Drug Trial Radar · NCT05426746
First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100
Last checked: Nov 19, 2026Latest source record: Sep 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Jul 5, 2022
Primary completion
May 18, 2023
Study completion May 18, 2023
Sponsor
- Lead sponsor
- Aqualung Therapeutics Corp.Industry
- Sponsor type
- Industry
- First posted
- Jun 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
ALT-100 is a monoclonal antibody developed by Aqualung Therapeutics Corp. as a treatment for Acute Respiratory Distress Syndrome (ARDS). ARDS can occur as a serious complication in patients with respiratory infections such as COVID-19 and Influenza or have acquired trauma to their lungs. 32 healthy male or female participants between the ages of 18 and 55 years will be enrolled into 4 cohorts of single ascending doses. The doses being investigated are 0.1mg/kg, 0.4mg/kg, 1mg/kg and 4mg/kg administered by intravenous infusion. Participants will be screened within 28 days of study treatment, be admitted to the clinical research unit for 3 nights and attend 7 outpatient visits on study days 8, 15, 22, 29, 60, 90 and 120 respectively. This study will collect data to evaluate safety and tolerability, Pharmacokinetics of ALT-100, Pharmacodynamics of ALT-100 and determine if Anti-drug Antibodies are produced in the participants.
Conditions
- ARDS, Human
Interventions
ALT-100Drug
intravenous infusion of drug substance diluted in 0.9% normal sterile saline
Normal SalineOther
intravenous infusion of placebo (0.9% normal sterile saline)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability will be assessed by the incidence, frequency and dose-relationship of all adverse eventsTime frame: up to 120 days post ALT-100 infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.